Improved Efficiency and Reliability of NGS Amplicon Sequencing Data Analysis for Genetic Diagnostic Procedures Using AGSA Software

Abstract EN

Screening for BRCA mutations in women with familial risk of breast or ovarian cancer is an ideal situation for high-throughput sequencing, providing large amounts of low cost data.

However, 454, Roche, and Ion Torrent, Thermo Fisher, technologies produce homopolymer-associated indel errors, complicating their use in routine diagnostics.

We developed software, named AGSA, which helps to detect false positive mutations in homopolymeric sequences.

Seventy-two familial breast cancer cases were analysed in parallel by amplicon 454 pyrosequencing and Sanger dideoxy sequencing for genetic variations of the BRCA genes.

All 565 variants detected by dideoxy sequencing were also detected by pyrosequencing.

Furthermore, pyrosequencing detected 42 variants that were missed with Sanger technique.

Six amplicons contained homopolymer tracts in the coding sequence that were systematically misread by the software supplied by Roche.

Read data plotted as histograms by AGSA software aided the analysis considerably and allowed validation of the majority of homopolymers.

As an optimisation, additional 250 patients were analysed using microfluidic amplification of regions of interest (Access Array Fluidigm) of the BRCA genes, followed by 454 sequencing and AGSA analysis.

AGSA complements a complete line of high-throughput diagnostic sequence analysis, reducing time and costs while increasing reliability, notably for homopolymer tracts.